HomeInsightsStock Comparison

Glenmark Pharmaceuticals Ltd vs Piramal Pharma Ltd Stock Comparison

Glenmark Pharmaceuticals Ltd vs Piramal Pharma Ltd Stock Comparison

Last Updated on: May 22, 2025

Key Highlights

  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 1420 as of 22 May 09:35.
  • The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 991.5 on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 27019 crore on March 2024 . This represents a CAGR of 35.97% over 5 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 17052 crore on March 2024 . This represents a CAGR of 44.51% over 2 years.
  • The revenue of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 3418 crore. This represent the decline of -100% The revenue of Piramal Pharma Ltd for the Mar '25 is ₹ 2812 crore as compare to the Dec '24 revenue of ₹ 2233 crore. This represent the growth of 25.92%.
  • The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 631.36 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Mar '25 is ₹ 619.24 crore as compare to the Dec '24 ebitda of ₹ 366.92 crore. This represent the growth of 68.77%.
  • The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Piramal Pharma Ltd changed from ₹ -98.58 crore to ₹ 153.5 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 1.37 % on March 2024 . This represents a CAGR of -23.44% over 5 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 3.72 % on March 2024 . This represents a CAGR of -40.95% over 3 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

About Piramal Pharma Ltd

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
  • It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
  • It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals announces board meeting date

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2...

Read more

13 May 2025 15:58

News

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001

IGI (Ichnos Glenmark Innovation), a global, fully integrated clinical-stage biotechnology ...

Read more

05 May 2025 19:16

News

Glenmark Pharma's US arm set to launch generic Adderall tablets

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroampheta...

Read more

17 Apr 2025 08:04

News

Glenmark Pharmaceuticals allots 12,653 equity shares under ESOP

Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the p...

Read more

17 Apr 2025 20:08

News

Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphe...

Read more

16 Apr 2025 19:53

News

Glenmark Pharmaceuticals Ltd slips for fifth straight session

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quot...

Read more

11 Apr 2025 13:35

Piramal Pharma Ltd News Hub

News

Piramal Pharma allots 35 lakh equity shares under ESOP

Piramal Pharma has allotted 35 lakh equity shares under ESOP on 21 May 2025. Consequent to...

Read more

21 May 2025 15:37

News

Board of Piramal Pharma recommends final dividend

Piramal Pharma announced that the Board of Directors of the Company at its meeting held on...

Read more

15 May 2025 10:18

News

Piramal Pharma's Turbhe facility successfully completes USFDA inspection

Piramal Pharma announced that the USFDA has issued an Establishment Inspection Report (EIR...

Read more

12 May 2025 12:47

News

Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA

According to the company's exchange filing, the US FDA conducted a general Good Manufactur...

Read more

12 May 2025 15:39

News

Piramal Pharma to conduct board meeting

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 14 May 2025...

Read more

30 Apr 2025 10:45

News

Piramal Pharma's Telangana unit starts production of general anesthesia drug Sevoflurane

This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility ...

Read more

02 Apr 2025 11:25

SWOT Analysis Of Piramal Pharma Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Piramal Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Piramal Pharma Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 40,629 Cr while Market cap of Piramal Pharma Ltd is 27,330 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Piramal Pharma Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Piramal Pharma Ltd?

As of May 22, 2025, the Glenmark Pharmaceuticals Ltd stock price is INR ₹1439.75. On the other hand, Piramal Pharma Ltd stock price is INR ₹206.15.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions